Cargando…
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
BACKGROUND: Sentinel lymph node biopsy (SNB) still remains a key procedure to appropriately stage melanoma patients and to select those who are candidate to novel treatments with immunotherapy and targeted therapy in the adjuvant setting. The impact of timing of SNB on disease-free survival (DFS) an...
Autores principales: | Mandalà, Mario, Galli, Francesca, Patuzzo, Roberto, Maurichi, Andrea, Mocellin, Simone, Rossi, Carlo R., Rulli, Eliana, Montesco, Maria, Quaglino, Pietro, Caliendo, Virginia, De Giorgi, Vincenzo, Merelli, Barbara, Caracò, Corrado, Piazzalunga, Dario, Labianca, Alice, Ribero, Simone, Senetta, Rebecca, Gianatti, Andrea, Valeri, Barbara, Massi, Daniela, Ascierto, Paolo A., Santinami, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391020/ https://www.ncbi.nlm.nih.gov/pubmed/32739767 http://dx.doi.org/10.1016/j.ejca.2020.07.001 |
Ejemplares similares
-
Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30–39]
por: Mandalà, Mario, et al.
Publicado: (2020) -
The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)
por: Tropea, Saveria, et al.
Publicado: (2022) -
Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study
por: Mandalà, M., et al.
Publicado: (2022) -
The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)
por: Elefanti, Lisa, et al.
Publicado: (2021) -
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)